Balancing the risks of thrombosis and bleeding following transcatheter aortic valve implantation: Current state-of-evidence

Current Pharmaceutical Design

Volumn 22, Issue 13, 2016, Pages 1904-1910

  Puri, Rishi ^a,b,c   Altisent, Omar Abdul Jawad ^a   Campelo Parada, Francisco ^a   del Trigo, Maria ^a   Regueiro, Ander ^a   Rodés Cabau, Josep ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bleeding; DAPT; TAVI; Thromobosis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG; RIVAROXABAN; WARFARIN;

ANEMIA; ANTICOAGULANT THERAPY; AORTA STENOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR THERAPEUTIC DEVICE; EMBOLIC DEFLECTOR DEVICE; EMBOLIC PROTECTION DEVICE; HEART ATRIUM ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; PERCUTANEOUS CORONARY INTERVENTION; PEROPERATIVE COMPLICATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; THROMBOSIS PREVENTION; TRANSCATHETER AORTIC VALVE IMPLANTATION; VASCULAR EQUIPMENT; ADVERSE EFFECTS; COMPLICATION; HEMORRHAGE; RISK ASSESSMENT; THROMBOSIS;

HEMORRHAGE; HUMANS; RISK ASSESSMENT; THROMBOSIS; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84964297920     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151208122628     Document Type: Article

References (78)

1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597-607.
2. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364: 2187-98.
3. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aorticvalve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370: 1790-8.
4. Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 2014; 63: 1972-81.
5. Rodes-Cabau J, Dauerman HL, Cohen MG, et al. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol 2013; 62: 2349-59.
6. Eggebrecht H, Schmermund A, Voigtlander T, Kahlert P, Erbel R, Mehta RH. Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention 2012; 8: 129-38.
7. Genereux P, Head SJ, Van Mieghem NM, et al. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies. J Am Coll Cardiol 2012; 59: 2317-26.
8. Panchal HB, Ladia V, Desai S, Shah T, Ramu V. A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events following transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis. Am J Cardiol 2013; 112: 850-60.
9. Khatri PJ, Webb JG, Rodes-Cabau J, et al. Adverse effects associated with transcatheter aortic valve implantation: a meta analysis of contemporary studies. Ann Intern Med 2013; 158: 35-46.
10. Athappan G, Gajulapalli RD, Sengodan P, et al. Influence of transcatheter aortic valve replacement strategy and valve design on stroke after transcatheter aortic valve replacement: a meta-analysis and systematic review of literature. J Am Coll Cardiol 2014; 63: 2101-10.
11. Généreux P, Cohen DJ, Williams MR, et al. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement insights from the PARTNER I Trial (Placement of aortic transcatheter valve). J Am Coll Cardiol 2014; 63: 1100-9.
12. Cordoba-Soriano JG, Puri R, Amat-Santos I, et al. Valve thrombosis following transcatheter aortic valve implantation: a systematic review. Rev Esp Cardiol (Engl Ed) 2015; 68: 198-204.
13. Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv 2015; 8: e001779.
14. Leetmaa T, Hansson NC, Leipsic J, et al. Early aortic transcatheter heart valve thrombosis: diagnostic value of contrastenhanced multidetector computed tomography. Circ Cardiovasc Interv 2015; 8: e001596
15. Davila-Roman VG, Murphy SF, Nickerson NJ, Kouchoukos NT, Schechtman KB, Barzilai B. Atherosclerosis of the ascending aorta is an independent predictor of long-term neurologic events and mortality. J Am Coll Cardiol 1999; 33: 1308-16.
16. Nicholls SJ, Hsu A, Wolski K, et al. Intravascular ultrasoundderived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010; 55: 2399-407.
17. Dalager S, Falk E, Kristensen IB, Paaske WP. Plaque in superficial femoral arteries indicates generalized atherosclerosis and vulnerability to coronary death: an autopsy study. J Vasc Surg 2008; 47: 296-302.
18. Iwakiri T, Yano Y, Sato Y, et al. Usefulness of carotid intimamedia thickness measurement as an indicator of generalized atherosclerosis: Findings from autopsy analysis. Atherosclerosis 2012; 225: 359-62.
19. Genereux P, Head SJ, Wood DA, et al. Transcatheter aortic valve implantation 10-year anniversary: review of current evidence and clinical implications. Eur Heart J 2012; 33: 2388-98.
20. Nombela-Franco L, Webb JG, de Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation 2012; 126: 3041-53.
21. Amat-Santos IJ, Rodes-Cabau J, Urena M, et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol 2012; 59: 178-88.
22. Tanawuttiwat T, O'Neill BP, Cohen MG, et al. New-onset atrial fibrillation after aortic valve replacement: comparison of transfemoral, transapical, transaortic, and surgical approaches. J Am Coll Cardiol 2014; 63: 1510-9.
23. Miller DC, Blackstone EH, Mack MJ, et al. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg 2012; 143: 832-843 e13.
24. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aorticvalve replacement for inoperable severe aortic stenosis. N Engl J Med 2012; 366: 1696-704.
25. Nombela-Franco L, Rodes-Cabau J, DeLarochelliere R, et al. Predictive factors, efficacy, and safety of balloon post-dilation after transcatheter aortic valve implantation with a balloon-expandable valve. JACC Cardiovasc Interv 2012; 5: 499-512.
26. Makkar RR, Jilaihawi H, Chakravarty T, et al. Determinants and outcomes of acute transcatheter valve-in-valve therapy or embolization: a study of multiple valve implants in the U.S. PARTNER trial (Placement of aortic transcatheter valve trial edwards sapien transcatheter heart valve). J Am Coll Cardiol 2013; 62: 418-30.
27. Hahn RT, Pibarot P, Webb J, et al. Outcomes with post-dilation following transcatheter aortic valve replacement: the PARTNER I trial (placement of aortic transcatheter valve). JACC Cardiovasc Interv 2014; 7: 781-9.
28. Kahlert P, Al-Rashid F, Dottger P, et al. Cerebral embolization during transcatheter aortic valve implantation: a transcranial doppler study. Circulation 2012; 126: 1245-55.
29. Polzin A, Schleicher M, Seidel H, et al. High on-treatment platelet reactivity in transcatheter aortic valve implantation patients. Eur J Pharmacol 2015; 751: 24-7.
30. Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 2012; 60: 1438-54.
31. Genereux P, Webb JG, Svensson LG, et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am Coll Cardiol 2012; 60: 1043-52.
32. Pilgrim T, Stortecky S, Luterbacher F, Windecker S, Wenaweser P. Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis. J Thromb Thrombolysis 2013; 35: 456-62.
33. Rodes-Cabau J. Transcatheter aortic valve implantation: current and future approaches. Nat Rev Cardiol 2012; 9: 15-29.
34. Nuis RJ, Piazza N, Van Mieghem NM, et al. In-hospital complications after transcatheter aortic valve implantation revisited according to the valve academic research consortium definitions. Catheter Cardiovasc Interv 2011; 78: 457-67.
35. Gurvitch R, Toggweiler S, Willson AB, et al. Outcomes and complications of transcatheter aortic valve replacement using a balloon expandable valve according to the Valve Academic Research Consortium (VARC) guidelines. EuroIntervention 2011; 7: 41-8.
36. Hayashida K, Lefevre T, Chevalier B, et al. Transfemoral aortic valve implantation new criteria to predict vascular complications. JACC Cardiovasc Interv 2011; 4: 851-8.
37. Toggweiler S, Gurvitch R, Leipsic J, et al. Percutaneous aortic valve replacement: vascular outcomes with a fully percutaneous procedure. J Am Coll Cardiol 2012; 59: 113-8.
38. Wong DR, Ye J, Cheung A, Webb JG, Carere RG, Lichtenstein SV. Technical considerations to avoid pitfalls during transapical aortic valve implantation. J Thorac Cardiovasc Surg 2010; 140: 196-202.
39. Borz B, Durand E, Godin M, et al. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis. Heart 2013; 99: 860-5.
40. Schymik G, Wurth A, Bramlage P, et al. Long-term results of transapical versus transfemoral TAVI in a real world population of 1000 patients with severe symptomatic aortic stenosis. Circ Cardiovasc Interv 2015; 8: e000761.
41. Allende R, Urena M, Cordoba JG, et al. Impact of the use of transradial versus transfemoral approach as secondary access in transcatheter aortic valve implantation procedures. Am J Cardiol 2014; 114: 1729-34.
42. Wynne DG, Rampat R, Trivedi U, et al. Transradial Secondary Arterial Access for Transcatheter Aortic Valve Implantation: Experience and Limitations. Heart, Lung Circ 2014; 24: 682-5.
43. Genereux P, Kodali S, Leon MB, et al. Clinical outcomes using a new crossover balloon occlusion technique for percutaneous closure after transfemoral aortic valve implantation. JACC Cardiovasc Interv 2011; 4: 861-7.
44. Nuis RJ, Rodes-Cabau J, Sinning JM, et al. Blood transfusion and the risk of acute kidney injury after transcatheter aortic valve implantation. Circ Cardiovasc Interv 2012; 5: 680-8.
45. Dauerman HL, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Bleeding complications in patients with anemia and acute myocardial infarction. Am J Cardiol 2005; 96: 1379-83.
46. Moretti C, D'Amico M, D'Ascenzo F, et al. Impact on prognosis of periprocedural bleeding after TAVI: mid-term follow-up of a multicenter prospective study. J Interv Cardiol 2014; 27: 293-9.
47. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366: 1686-95.
48. Halliday BP, Dworakowski R, Brickham B, Wendler O, MacCarthy P. Usefulness of periprocedural bleeding to predict outcome after transcatheter aortic valve implantation. Am J Cardiol 2012; 109: 724-8.
49. Tchetche D, Van der Boon RM, Dumonteil N, et al. Adverse impact of bleeding and transfusion on the outcome posttranscatheter aortic valve implantation: insights from the pooled rotterdam-milano-toulouse in collaboration plus (PRAGMATIC Plus) initiative. Am Heart J 2012; 164: 402-9.
50. Van Mieghem NM, Tchetche D, Chieffo A, et al. Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation. Am J Cardiol 2012; 110: 1361-7.
51. Genereux P, Cohen DJ, Mack M, et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. J Am Coll Cardiol 2014; 64: 2605-15.
52. Blackshear JL, Wysokinska EM, Safford RE, et al. Indexes of von Willebrand factor as biomarkers of aortic stenosis severity (from the biomarkers of aortic stenosis severity [BASS] study). Am J Cardiol 2013; 111: 374-81.
53. Spangenberg T, Budde U, Schewel D, et al. Treatment of acquired von Willebrand syndrome in aortic stenosis with transcatheter aortic valve replacement. JACC Cardiovasc Interv 2015; 8: 692-700.
54. Holmes DR, Jr., Mack MJ, Kaul S, et al. 2012 ACCF/AATS/ SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 2012; 59: 1200-54.
55. Webb J, Rodes-Cabau J, Fremes S, et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement. Can J Cardiol 2012; 28: 520-8.
56. Joint Task Force on the Management of Valvular Heart Disease of the European Society of C, European Association for Cardio-Thoracic S, Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-96.
57. Bernelli C, Chieffo A, Montorfano M, et al. Usefulness of baseline activated clotting time-guided heparin administration in reducing bleeding events during transfemoral transcatheter aortic valve implantation. JACC Cardiovasc Interv 2014; 7: 140-51.
58. Van Mieghem NM, El Faquir N, Rahhab Z, et al. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. JACC Cardiovasc Interv 2015; 8: 718-24.
59. Kini A, Yu J, Cohen MG, et al. Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention 2014; 10: 312-9.
60. Sergie Z, Lefevre T, Van Belle E, et al. Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. J Thromb Thrombolysis 2013; 35: 483-93.
61. Silvain J, Beygui F, Barthelemy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012; 344: e553.
62. Ruiz CE. Optimizing transcatheter aortic valve sizing and minimizing vascular complications. J Am Coll Cardiol 2012; 59: 128-9.
63. Buchanan GL, Chieffo A, Montorfano M, et al. A "modified crossover technique" for vascular access management in high-risk patients undergoing transfemoral transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2013; 81: 579-83.
64. Hayashida K, Lefevre T, Chevalier B, et al. True percutaneous approach for transfemoral aortic valve implantation using the Prostar XL device: impact of learning curve on vascular complications. JACC Cardiovasc Interv 2012; 5: 207-14.
65. Rodes-Cabau J, Kahlert P, Neumann FJ, et al. Feasibility and exploratory efficacy evaluation of the Embrella Embolic Deflector system for the prevention of cerebral emboli in patients undergoing transcatheter aortic valve replacement: the PROTAVI-C pilot study. JACC Cardiovasc Interv 2014; 7: 1146-55.
66. Baumbach A, Mullen M, Brickman AM, et al. Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. EuroIntervention 2015; 11: 75-84.
67. Ussia GP, Scarabelli M, Mule M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108: 1772-6.
68. Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 2014; 174: 624-7.
69. Durand E, Blanchard D, Chassaing S, et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2014; 113: 355-60.
70. Hassell ME, Hildick-Smith D, Durand E, et al. Antiplatelet therapy following transcatheter aortic valve implantation. Heart 2015; 101: 1118-25.
71. Gandhi S, Schwalm JD, Velianou JL, Natarajan MK, Farkouh ME. Comparison of dual-antiplatelet therapy to mono-antiplatelet therapy after transcatheter aortic valve implantation: Systematic review and meta-analysis. Can J Cardiol 2015; 31: 775-84.
72. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
73. Mok M, Urena M, Nombela-Franco L, et al. Clinical and prognostic implications of existing and new-onset atrial fibrillation in patients undergoing transcatheter aortic valve implantation. J Thromb Thrombolysis 2013; 35: 450-5.
74. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33: 1500-10.
75. Wenaweser P, Pilgrim T, Guerios E, et al. Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. EuroIntervention 2011; 7: 541-8.
76. Abdel-Wahab M, Mostafa AE, Geist V, et al. Comparison of outcomes in patients having isolated transcatheter aortic valve implantation versus combined with preprocedural percutaneous coronary intervention. Am J Cardiol 2012; 109: 581-6.
77. Gasparetto V, Fraccaro C, Tarantini G, et al. Safety and effectiveness of a selective strategy for coronary artery revascularization before transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2013; 81: 376-83.
78. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-15.